Cargando…
Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the form...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258847/ https://www.ncbi.nlm.nih.gov/pubmed/30232131 http://dx.doi.org/10.1128/JCM.00961-18 |
_version_ | 1783374569766125568 |
---|---|
author | da Silva Brito, Vanessa Santos, Fred Luciano Neves Gonçalves, Noilson Lazaro Sousa Araujo, Thessika Hialla Almeida Nascimento, Davi Silva Vale Pereira, Felicidade Mota Boa-Sorte, Ney Cristian Amaral Grassi, Maria Fernanda Rios Caterino-de-Araujo, Adele Galvão-Castro, Bernardo |
author_facet | da Silva Brito, Vanessa Santos, Fred Luciano Neves Gonçalves, Noilson Lazaro Sousa Araujo, Thessika Hialla Almeida Nascimento, Davi Silva Vale Pereira, Felicidade Mota Boa-Sorte, Ney Cristian Amaral Grassi, Maria Fernanda Rios Caterino-de-Araujo, Adele Galvão-Castro, Bernardo |
author_sort | da Silva Brito, Vanessa |
collection | PubMed |
description | Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the format of HTLV screening tests, as well as newly introduced chemiluminescence assays (CLIAs), a systematic evaluation of the accuracy of currently available commercial tests is warranted. We aimed to assess the performance of commercially available screening tests for HTLV infection diagnosis. A diagnostic accuracy study was conducted on a panel of 397 plasma samples: 200 HTLV-negative plasma samples, 170 HTLV-positive plasma samples, and 27 plasma samples indeterminate by Western blotting (WB). WB-indeterminate samples (i.e., those yielding no specific bands for HTLV-1 and/or HTLV-2) were assessed by PCR, and the results were used to compare agreement among the commercially available ELISA screening tests. For performance analysis, WB-indeterminate samples were excluded, resulting in a final study panel of 370 samples. Three ELISA kits (Murex HTLV-1/2 [Murex], anti-HTLV-1/2 SYM Solution [SYM Solution], and Gold ELISA HTLV-1/2 [Gold ELISA]) and one CLIA kit (Architect rHTLV-1/2) were evaluated. All screening tests demonstrated 100% sensitivity. Concerning the HTLV-negative samples, the SYM Solution and Gold ELISA kits had specificity values of >99.5%, while the Architect rHTLV-1/2 test presented 98.1% specificity, followed by Murex, which had a specificity of 92.0%. Regarding the 27 samples with WB-indeterminate results, after PCR confirmation, all ELISA kits showed 100% sensitivity but low specificity. Accuracy findings were corroborated by the use of Cohen's kappa value, which evidenced slight and fair agreement between PCR analysis and ELISAs for HTLV infection diagnosis. Based on the data, we believe that all evaluated tests can be safely used for HTLV infection screening. |
format | Online Article Text |
id | pubmed-6258847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-62588472018-12-13 Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil da Silva Brito, Vanessa Santos, Fred Luciano Neves Gonçalves, Noilson Lazaro Sousa Araujo, Thessika Hialla Almeida Nascimento, Davi Silva Vale Pereira, Felicidade Mota Boa-Sorte, Ney Cristian Amaral Grassi, Maria Fernanda Rios Caterino-de-Araujo, Adele Galvão-Castro, Bernardo J Clin Microbiol Immunoassays Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the format of HTLV screening tests, as well as newly introduced chemiluminescence assays (CLIAs), a systematic evaluation of the accuracy of currently available commercial tests is warranted. We aimed to assess the performance of commercially available screening tests for HTLV infection diagnosis. A diagnostic accuracy study was conducted on a panel of 397 plasma samples: 200 HTLV-negative plasma samples, 170 HTLV-positive plasma samples, and 27 plasma samples indeterminate by Western blotting (WB). WB-indeterminate samples (i.e., those yielding no specific bands for HTLV-1 and/or HTLV-2) were assessed by PCR, and the results were used to compare agreement among the commercially available ELISA screening tests. For performance analysis, WB-indeterminate samples were excluded, resulting in a final study panel of 370 samples. Three ELISA kits (Murex HTLV-1/2 [Murex], anti-HTLV-1/2 SYM Solution [SYM Solution], and Gold ELISA HTLV-1/2 [Gold ELISA]) and one CLIA kit (Architect rHTLV-1/2) were evaluated. All screening tests demonstrated 100% sensitivity. Concerning the HTLV-negative samples, the SYM Solution and Gold ELISA kits had specificity values of >99.5%, while the Architect rHTLV-1/2 test presented 98.1% specificity, followed by Murex, which had a specificity of 92.0%. Regarding the 27 samples with WB-indeterminate results, after PCR confirmation, all ELISA kits showed 100% sensitivity but low specificity. Accuracy findings were corroborated by the use of Cohen's kappa value, which evidenced slight and fair agreement between PCR analysis and ELISAs for HTLV infection diagnosis. Based on the data, we believe that all evaluated tests can be safely used for HTLV infection screening. American Society for Microbiology 2018-11-27 /pmc/articles/PMC6258847/ /pubmed/30232131 http://dx.doi.org/10.1128/JCM.00961-18 Text en Copyright © 2018 da Silva Brito et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Immunoassays da Silva Brito, Vanessa Santos, Fred Luciano Neves Gonçalves, Noilson Lazaro Sousa Araujo, Thessika Hialla Almeida Nascimento, Davi Silva Vale Pereira, Felicidade Mota Boa-Sorte, Ney Cristian Amaral Grassi, Maria Fernanda Rios Caterino-de-Araujo, Adele Galvão-Castro, Bernardo Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title | Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title_full | Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title_fullStr | Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title_full_unstemmed | Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title_short | Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil |
title_sort | performance of commercially available serological screening tests for human t-cell lymphotropic virus infection in brazil |
topic | Immunoassays |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258847/ https://www.ncbi.nlm.nih.gov/pubmed/30232131 http://dx.doi.org/10.1128/JCM.00961-18 |
work_keys_str_mv | AT dasilvabritovanessa performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT santosfredlucianoneves performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT goncalvesnoilsonlazarosousa performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT araujothessikahiallaalmeida performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT nascimentodavisilvavale performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT pereirafelicidademota performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT boasorteneycristianamaral performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT grassimariafernandarios performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT caterinodearaujoadele performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil AT galvaocastrobernardo performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil |